FDA’s recent efforts to enhance accessibility to OTC drug products have set the stage for a wave of approved switches in the industry – a development being warmly embraced by non-prescription drug companies. This panel will:

• Analyzing the high-profile switches shaping the OTC industry landscape
  • Opill
  • Naloxone
• Explore what FDA has considered in approving the latest switches and hurdles industry may face in obtaining future switches
• Assessing the significance of the Opill switch and its implications on new opportunities for RX-OTC switches, particularly in the area of women’s health